HPTP-beta Inhibitor Combination Therapy for Ocular Vascular Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular diseases such as diabetic macular edema, age-related macular degeneration, and choroidal neovascularization have limited success and often result in high recurrence rates or vision loss, with existing interventions like laser photocoagulation and low-dose radiation being ineffective in inducing regression of choroidal neovascularization.
Innovation Solution
Administration of a compound formula, specifically a Human Protein Tyrosine Phosphatase-beta (HPTP-β) inhibitor, in combination with anti-VEGF agents, to stabilize ocular vasculature and counteract the stimulation caused by VEGF, thereby treating ocular diseases characterized by vascular instability and neovascularization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If laser photocoagulation or low-dose radiation is used to treat ocular diseases, then treatment is administered, but the treatments are ineffective in inducing regression of choroidal neovascularization and result in high recurrence rates
Solution Approach 1:
The patent changes the pharmacological parameter by introducing HPTP-β inhibitors with specific molecular structures (compounds of Formula I) that differ fundamentally from existing treatments. These compounds target a different biochemical pathway (HPTP-β enzyme inhibition) compared to conventional therapies, thereby achieving regression of choroidal neovascularization where previous treatments failed.
Solution Approach 2:
The invention combines HPTP-β inhibitors with anti-VEGF agents in a composite therapeutic approach. This combination therapy leverages the complementary mechanisms of action: HPTP-β inhibition stabilizes ocular vasculature while anti-VEGF agents counteract VEGF stimulation, creating a synergistic effect that reduces recurrence and improves treatment reliability.
2Reliability
If existing treatments are administered for ocular diseases, then some therapeutic effect is achieved, but vision loss occurs and disease reversal is not sustained after withdrawal of treatment
Solution Approach 1:
The HPTP-β inhibitors perform preliminary stabilization of the ocular vasculature before and during the treatment course. By pre-stabilizing vascular structures and inhibiting phosphatase activity that promotes vascular instability, the treatment creates a foundation that sustains disease reversal effects even after the medication is withdrawn, preventing vision loss.
Solution Approach 2:
The combination therapy establishes a feedback mechanism where HPTP-β inhibition continuously stabilizes vasculature in response to disease progression signals, while anti-VEGF agents respond to VEGF levels. This coordinated feedback system maintains therapeutic effect and sustains disease reversal beyond treatment withdrawal.
Data Source
AI summary
Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.